Antibodies to Digoxin for Bipolar Disorder

• Status: Completed
• Trial end date: 2009-02-01
• Target enrollment: 0
• Participant gender: All

Summary

Subjects suffering from bipolar disorders treated with specific medications will give their informed concent and will receive intravenously only one dose of Digoxin antibodies (Fab). Their response to this therapy will be measured accordingly.Previous medications will be not changed A base line serum Endogenous Digitalis-like Compounds (DLC)levels will be measured using a specific laboratory technique and these compounds will be measured at 6 and 24 hours after Fab therapy.

Patients also will be followed using clinical and psychological tests

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Rambam Health Care Campus
• Treatments: Antibodies; Digoxin; Immunoglobulins

Criteria

Inclusion Criteria:

• Admitted patients suffering from Bipolar Disorder

• abillity to give informed concent

Exclusion Criteria:

• Allergy to Digoxin Antibodies

• Renal and Liver function impairment

• Liver Cirrhosis

• Asthma

• Patients on Digoxin or Digitoxin

• Patients receiving Aldactone therapy

• Heart A-V Block

• Hypo or Hyperkalemia on admission

• Potential Suicidal Behaviour